Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 5:11:100274.
doi: 10.1016/j.prdoa.2024.100274. eCollection 2024.

Role of alpha-synuclein seed amplification assay in Parkinson's disease clinical trials: A case of misdiagnosis

Affiliations

Role of alpha-synuclein seed amplification assay in Parkinson's disease clinical trials: A case of misdiagnosis

Emily Tharp et al. Clin Park Relat Disord. .

Abstract

•Early differentiation between PD and atypical parkinsonism is challenging.•Variability in diagnosis can weaken statistical power in trials.•Precise diagnostic tools are needed for trial population homogeneity.•This patient initially diagnosed with PD, was diagnosed with MSA via CSF αSyn-SAA.•Adding αSyn-SAA to inclusion criteria could enhance subject selection in trials.

Keywords: Alpha-synuclein; Clinical trial; Multiple System Atrophy; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mya C. Schiess and Mohammad Shahnawaz have received financial support from grants provided by the Michael J. Fox Foundation (MJFF) for Parkinson’s Research. Mohammad Shahnawaz is the inventor of the patent for PMCA under #US10989718B2, licensed to the University of Texas Health Science Center at Houston and Amprion Inc. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Clinical and neuroimaging characteristics in a subject initially misdiagnosed with Parkinson’s Disease whose diagnosis was subsequently corrected as Multiple System Atrophy during a Phase 2b clinical trial using alpha-synuclein seed amplification (αSyn-SAA). A. Longitudinal changes in motor and non-motor assessments. B-D. Baseline magnetic resonance imaging (MRI) without contrast sequences in T2 with axial sections of the cerebellum, cerebellar nuclei, middle cerebellar peduncles (B), midbrain (C), and basal ganglia (D), showing age-expected mild atrophy with no other relevant changes. E. α-Syn-SAA from the patient’s CSF sample using the protein misfolding cyclic amplification (PMCA) method showing a typical MSA aggregation pattern5: faster aggregation but lower maximum fluorescence compared to a standard PD control. A.U.: Arbitrary Units. DBP: Diastolic Blood Pressure. HR: Heart Rate. MDS-UPDRS: The Movement Disorder Society Unified Parkinson's Disease Rating Scale. MSA: Multiple System Atrophy. NA: Not Available. NMSQ: Non-Motor Symptoms Questionnaire. T50: Time (hours) to reach 50% of maximum aggregation, and Fmax: The maximum ThT fluorescence at the plateau. SBP: Systolic Blood Pressure. PD: Parkinson’s Disease. Error bars indicate the standard error of the mean (SEM).

References

    1. McFarthing K., Buff S., Rafaloff G., Dominey T., Wyse R.K., Stott S.R.W. Parkinson's disease drug therapies in the clinical trial pipeline: 2020. J. Parkinsons Dis. 2020;10(3):757–774. - PMC - PubMed
    1. Wullner U., Borghammer P., Choe C.U., Csoti I., Falkenburger B., Gasser T., et al. The heterogeneity of Parkinson's disease. J. Neural Transm. (Vienna) 2023;130(6):827–838. - PMC - PubMed
    1. Rizzo G., Copetti M., Arcuti S., Martino D., Fontana A., Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016;86(6):566–576. - PubMed
    1. Low P.A., Reich S.G., Jankovic J., Shults C.W., Stern M.B., Novak P., et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710–719. - PMC - PubMed
    1. Shahnawaz M., Mukherjee A., Pritzkow S., Mendez N., Rabadia P., Liu X., et al. Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. Nature. 2020;578(7794):273–277. - PMC - PubMed

LinkOut - more resources